Shares of Hikma Pharmaceuticals Plc (OTCMKTS:HKMPF – Get Free Report) hit a new 52-week high during trading on Wednesday. The stock traded as high as $23.5850 and last traded at $23.5850, with a volume of 200 shares trading hands. The stock had previously closed at $23.41.
Analysts Set New Price Targets
HKMPF has been the topic of a number of analyst reports. Citigroup restated a “buy” rating on shares of Hikma Pharmaceuticals in a research note on Wednesday, August 12th. Barclays upgraded Hikma Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Tuesday, September 8th. One investment analyst has rated the stock with a Buy rating and one has given a Hold rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy”.
Check Out Our Latest Research Report on HKMPF
Hikma Pharmaceuticals Stock Performance
The stock’s 50-day moving average is $21.85 and its two-hundred day moving average is $20.24.
About Hikma Pharmaceuticals
Hikma Pharmaceuticals plc is a multinational pharmaceutical company that develops, manufactures and markets a broad range of generic, branded and specialty medicines. Its portfolio includes injectable medicines, oral solid-dose products, inhalation products and other treatments used in hospitals, pharmacies and community-care settings.
The company operates through three principal businesses: Injectables, Generics and Branded Medicines. Hikma supplies injectable products to hospitals and healthcare providers, offers generic medicines primarily in the United States, and markets branded and licensed medicines across the Middle East and North Africa.
See Also
- Five stocks we like better than Hikma Pharmaceuticals
- Riot’s $28B Lease Shows Why Location and Contracts Matter in AI
- These 3 Underperforming Stocks Are Seeing Notable CEO Insider Trades
- GE Aerospace Has a $170 Billion Backlog, But Is the Stock Worth the Premium?
- Google’s Credit Backstop May Be TeraWulf’s Biggest Advantage
Receive News & Ratings for Hikma Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
